Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation

R. H. Collins, L. A. Pineiro, J. J. Nemunaitis, V. K. Jain, D. Waxman, W. V. Miller, J. W. Fay

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Patients who experience relapse after allogeneic bone marrow transplantation have a poor prognosis. However, preclinical and clinical data have strongly suggested the existence of an immune-mediated anti-tumor effect of allogeneic bone marrow transplantation. This effect, termed graft-versus- leukemia, may be harnessed purposefully in patients with posttransplant relapses by the administration of immune cells obtained by leukapheresis of the original bone marrow donor. Study Design and Methods: Thirteen patients with persistent or recurrent hematologic malignancy after HLA-matched sibling-donor allogeneic bone marrow transplantation were treated with transfusion of burly coat cells collected from the original bone marrow donors. Mononuclear cell doses ranged from 1.18 to 4.28 x 108 per kg. Alpha- interferon (1.5-3 x 106 U/m2 3-5x/week) was given to seven patients. Patients were observed for the development of graft-versus-host disease and disease response. Results: Three of five patients with chronic myelogenous leukemia had complete remissions. One of five patients with active acute leukemia attained complete remission. A sixth acute leukemia patient treated with buffy coat transfusion after the induction of remission with chemotherapy relapsed 12 months later. One patient with myeloma had a complete but transient response. A patient with Hodgkin's disease did not respond. Four patients remain in remission 4, 16, 17, and 29 months after attaining complete remission. Graft-versus-host disease occurred in eight patients, including all of those with a complete response. One patient developed transient pancytopenia. Conclusion: The transfusion of donor buffy coat cells has significant anti-tumor activity in patients with relapsed hematologic malignancy after allogeneic bone marrow transplantation. This effect is strongly associated with graft-versus-host disease.

Original languageEnglish (US)
Pages (from-to)891-898
Number of pages8
JournalTransfusion
Volume35
Issue number11
StatePublished - 1995

Fingerprint

Glycocalyx
Homologous Transplantation
Bone Marrow Transplantation
Tissue Donors
Neoplasms
Therapeutics
Graft vs Host Disease
Leukemia
Hematologic Neoplasms
Bone Marrow
Leukapheresis
Remission Induction
Recurrence
Pancytopenia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hodgkin Disease
Interferon-alpha

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Collins, R. H., Pineiro, L. A., Nemunaitis, J. J., Jain, V. K., Waxman, D., Miller, W. V., & Fay, J. W. (1995). Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Transfusion, 35(11), 891-898.

Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. / Collins, R. H.; Pineiro, L. A.; Nemunaitis, J. J.; Jain, V. K.; Waxman, D.; Miller, W. V.; Fay, J. W.

In: Transfusion, Vol. 35, No. 11, 1995, p. 891-898.

Research output: Contribution to journalArticle

Collins, RH, Pineiro, LA, Nemunaitis, JJ, Jain, VK, Waxman, D, Miller, WV & Fay, JW 1995, 'Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation', Transfusion, vol. 35, no. 11, pp. 891-898.
Collins, R. H. ; Pineiro, L. A. ; Nemunaitis, J. J. ; Jain, V. K. ; Waxman, D. ; Miller, W. V. ; Fay, J. W. / Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. In: Transfusion. 1995 ; Vol. 35, No. 11. pp. 891-898.
@article{d9eb4f4eb31a43a6a67c4b118f8aa3d7,
title = "Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation",
abstract = "Background: Patients who experience relapse after allogeneic bone marrow transplantation have a poor prognosis. However, preclinical and clinical data have strongly suggested the existence of an immune-mediated anti-tumor effect of allogeneic bone marrow transplantation. This effect, termed graft-versus- leukemia, may be harnessed purposefully in patients with posttransplant relapses by the administration of immune cells obtained by leukapheresis of the original bone marrow donor. Study Design and Methods: Thirteen patients with persistent or recurrent hematologic malignancy after HLA-matched sibling-donor allogeneic bone marrow transplantation were treated with transfusion of burly coat cells collected from the original bone marrow donors. Mononuclear cell doses ranged from 1.18 to 4.28 x 108 per kg. Alpha- interferon (1.5-3 x 106 U/m2 3-5x/week) was given to seven patients. Patients were observed for the development of graft-versus-host disease and disease response. Results: Three of five patients with chronic myelogenous leukemia had complete remissions. One of five patients with active acute leukemia attained complete remission. A sixth acute leukemia patient treated with buffy coat transfusion after the induction of remission with chemotherapy relapsed 12 months later. One patient with myeloma had a complete but transient response. A patient with Hodgkin's disease did not respond. Four patients remain in remission 4, 16, 17, and 29 months after attaining complete remission. Graft-versus-host disease occurred in eight patients, including all of those with a complete response. One patient developed transient pancytopenia. Conclusion: The transfusion of donor buffy coat cells has significant anti-tumor activity in patients with relapsed hematologic malignancy after allogeneic bone marrow transplantation. This effect is strongly associated with graft-versus-host disease.",
author = "Collins, {R. H.} and Pineiro, {L. A.} and Nemunaitis, {J. J.} and Jain, {V. K.} and D. Waxman and Miller, {W. V.} and Fay, {J. W.}",
year = "1995",
language = "English (US)",
volume = "35",
pages = "891--898",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation

AU - Collins, R. H.

AU - Pineiro, L. A.

AU - Nemunaitis, J. J.

AU - Jain, V. K.

AU - Waxman, D.

AU - Miller, W. V.

AU - Fay, J. W.

PY - 1995

Y1 - 1995

N2 - Background: Patients who experience relapse after allogeneic bone marrow transplantation have a poor prognosis. However, preclinical and clinical data have strongly suggested the existence of an immune-mediated anti-tumor effect of allogeneic bone marrow transplantation. This effect, termed graft-versus- leukemia, may be harnessed purposefully in patients with posttransplant relapses by the administration of immune cells obtained by leukapheresis of the original bone marrow donor. Study Design and Methods: Thirteen patients with persistent or recurrent hematologic malignancy after HLA-matched sibling-donor allogeneic bone marrow transplantation were treated with transfusion of burly coat cells collected from the original bone marrow donors. Mononuclear cell doses ranged from 1.18 to 4.28 x 108 per kg. Alpha- interferon (1.5-3 x 106 U/m2 3-5x/week) was given to seven patients. Patients were observed for the development of graft-versus-host disease and disease response. Results: Three of five patients with chronic myelogenous leukemia had complete remissions. One of five patients with active acute leukemia attained complete remission. A sixth acute leukemia patient treated with buffy coat transfusion after the induction of remission with chemotherapy relapsed 12 months later. One patient with myeloma had a complete but transient response. A patient with Hodgkin's disease did not respond. Four patients remain in remission 4, 16, 17, and 29 months after attaining complete remission. Graft-versus-host disease occurred in eight patients, including all of those with a complete response. One patient developed transient pancytopenia. Conclusion: The transfusion of donor buffy coat cells has significant anti-tumor activity in patients with relapsed hematologic malignancy after allogeneic bone marrow transplantation. This effect is strongly associated with graft-versus-host disease.

AB - Background: Patients who experience relapse after allogeneic bone marrow transplantation have a poor prognosis. However, preclinical and clinical data have strongly suggested the existence of an immune-mediated anti-tumor effect of allogeneic bone marrow transplantation. This effect, termed graft-versus- leukemia, may be harnessed purposefully in patients with posttransplant relapses by the administration of immune cells obtained by leukapheresis of the original bone marrow donor. Study Design and Methods: Thirteen patients with persistent or recurrent hematologic malignancy after HLA-matched sibling-donor allogeneic bone marrow transplantation were treated with transfusion of burly coat cells collected from the original bone marrow donors. Mononuclear cell doses ranged from 1.18 to 4.28 x 108 per kg. Alpha- interferon (1.5-3 x 106 U/m2 3-5x/week) was given to seven patients. Patients were observed for the development of graft-versus-host disease and disease response. Results: Three of five patients with chronic myelogenous leukemia had complete remissions. One of five patients with active acute leukemia attained complete remission. A sixth acute leukemia patient treated with buffy coat transfusion after the induction of remission with chemotherapy relapsed 12 months later. One patient with myeloma had a complete but transient response. A patient with Hodgkin's disease did not respond. Four patients remain in remission 4, 16, 17, and 29 months after attaining complete remission. Graft-versus-host disease occurred in eight patients, including all of those with a complete response. One patient developed transient pancytopenia. Conclusion: The transfusion of donor buffy coat cells has significant anti-tumor activity in patients with relapsed hematologic malignancy after allogeneic bone marrow transplantation. This effect is strongly associated with graft-versus-host disease.

UR - http://www.scopus.com/inward/record.url?scp=0029555186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029555186&partnerID=8YFLogxK

M3 - Article

C2 - 8604484

AN - SCOPUS:0029555186

VL - 35

SP - 891

EP - 898

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 11

ER -